Study related clinical trial N. of patients Type of cetuximab treatment line of therapy main results Zhang et al.  [13] phase II (ImClone 0144) 39 cetuximab monotherapy 3rd line Shorter PFS for patients with FCGR2A R/R or FCGR3A V/V Bibeau et al.  [19] None 69 cetuximab + irinotecan 3rd line PFS advantage for FCGR3A V/V Calemma et al. [20] None 49 cetuximab + various chemotherapy 1st, 2nd and 3rd line Response Rate and PFS advantage for FCGR3A V/V Rodríguez et al. [21] None 44 cetuximab+various chemotherapy 1st, 2nd and 3rd line higher percentage of patients progressing within 6 months in the FCGR2A R/R and FCGR3A F/F groups Etienne-Grimaldi et al. [15] phase II (CETUFTIRI) 51 cetuximab + UFT + irinotecan 1st line Shorter OS for FCGR3A F/F Park et al. [22] None 107 cetuximab+irinotecan 3rd line no significant association of FCGR SNPs with outcome Dahan et al. [23] None 56 cetuximab+various chemotherapy 1st, 2nd and 3rd line Shorter OS for FCGR3A V/V Zhang et al. [24] phase II (BOND-2) 65 cetuximab + bevacizumab ± irinotecan 3rd line Increased response for FCGR3A F/F only in cetuximab + bevacizumab treated patients Paez et al. [25] None 104 cetuximab + various chemotherapy 1st, 2nd and 3rd line no significant association of FCGR SNPs with outcome Pander et al. [16] phase III (CAIRO-2) 122 cetuximab + oxaliplatin + capecitabine + bevacizumab 1st line PFS advantage for FCGR3A F/F Graziano et al. [27] None 110 cetuximab + irinotecan 3rd line no significant association of FCGR SNPs with outcome Negri et al. [26] None 86 cetuximab + various chemotherapy 1st, 2nd and 3rd line no significant association of FCGR SNPs with outcome Abbreviation: PFS: progression Free Survival; OS: Overall Survival; SNPs: Single Nucleotide Polymorphisms

Table 1: Main characteristics of retrieved retrospective studies.